This article is more than 5 years old. Information may no longer be current.

VEGF Trap-Eye recommended for approval for wet AMD treatment in Europe

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The European Committee for Medicinal Products for Human Use recommended VEGF Trap-Eye for approval for the treatment of neovascular age-related macular degeneration, according to a news release from Bayer HealthCare.

VEGF Trap-Eye (aflibercept), known as Eylea and marketed by Regeneron in the United States, was approved in November 2011 by the U.S. Food and Drug Administration for the treatment of wet AMD. Earlier this month, the FDA approved it for the treatment of macular edema after central retinal vein occlusion.

The European Commission is expected to make a decision on the approval in the fourth quarter, the release said.

Bayer plans to submit aflibercept for European marketing authorization for CRVO before the end of the year, the release said.